Depression, cognition, and GLP-1 receptors: Heterogeneity and therapeutic prospects.

Med (New York, N.Y.)2026PMID: 41519115

View on PubMed DOI: 10.1016/j.medj.2025.100954

Plain Language Summary

Commentary and editorial analysis responding to a placebo-controlled trial (Badulescu et al.) reporting semaglutide's potential improvements in attention and memory in depression, examining GLP-1R mechanisms in cognitive-emotional circuits, heterogeneity in depressive phenotypes, and the therapeutic prospects for GLP-1 RAs in cognitive impairments associated with depression. Contextualizes the promising cognitive signal within the broader GLP-1 RA neuropsychiatric evidence base. Provides expert perspective on semaglutide's cognitive benefits in depression—an important comorbidity of obesity where improved cognitive function could enhance treatment adherence and quality of life.

Abstract

Cognitive impairments in depression, driven by both the illness per se and low-grade systemic inflammation, markedly reduce functional capacity and quality of life among patients who suffer. Findings from Badulescu et al.'s placebo-controlled trial reported that semaglutide, a GLP-1 receptor agonist, may improve attention and memory, although there was no significant improvement in overall depressive symptoms.

Authors

Chen, Mu-Hong; Bai, Ya-Mei; Tsai, Shih-Jen